MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2026-03-31, NAMS has $732,643K in assets. $67,421K in debts. $457,607K in cash and cash equivalents.

Balance Sheets Overview

Current Ratio
976.02%
Quick Ratio
976.02%
Cash Ratio
678.73%
Debt to Asset Ratio
9.20%
Unit: Thousand (K) dollars
Assets Breakdown
    • Cash and cash equivalents
    • Marketable securities, current
    • Marketable securities, net of cu...
    • Others
Liabilities Breakdown
    • Additional paid-in capital
    • Accumulated loss
    • Derivative warrant liabilities
    • Others

Balance Sheets
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Cash and cash equivalents
457,607 490,002 538,407 563,864
Prepayments and other receivables
20,603 38,138 28,074 30,688
Marketable securities, current
178,498 146,239 164,539 175,298
Restricted cash
1,336 1,321 1,308 -
Total current assets
658,044 675,700 732,328 769,850
Marketable securities, net of current portion
71,239 92,609 53,091 44,172
Property, plant and equipment, net
379 383 323 312
Operating right of use asset
21 185 246 308
Intangible assets
375 407 439 470
Long term prepaid expenses
2,585 ---
Total assets
732,643 769,284 786,427 815,112
Accounts payable
8,090 8,970 3,632 5,895
Accrued expenses and other current liabilities
5,092 15,422 10,098 9,460
Deferred revenue, current
3,987 3,987 --
Lease liability, current
23 136 181 225
Derivative warrant liabilities
50,229 57,272 44,361 20,932
Total current liabilities
67,421 85,787 58,272 36,512
Lease liability, net of current portion
-66 85 103
Total liabilities
67,421 85,853 58,357 36,615
Ordinary shares
14,594 14,278 14,107 14,014
Additional paid-in capital
1,457,238 1,426,750 1,396,790 1,375,618
Accumulated loss
-810,831 -762,390 -687,467 -615,462
Accumulated other comprehensive income
4,221 4,793 4,640 4,327
Total shareholders' equity
665,222 683,431 728,070 778,497
Total liabilities and shareholders' equity
732,643 769,284 786,427 815,112
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Balance Sheets

Cash and cashequivalents$457,607K Marketable securities,current$178,498K Prepayments and otherreceivables$20,603K Restricted cash$1,336K Total current assets$658,044K Marketable securities, netof current portion$71,239K Long term prepaidexpenses$2,585K Property, plant andequipment, net$379K Intangible assets$375K Operating right of useasset$21K Total assets$732,643K Total liabilities andshareholders' equity$732,643K Total shareholders'equity$665,222K Total liabilities$67,421K Accumulated loss-$810,831K Additional paid-in capital$1,457,238K Total currentliabilities$67,421K Ordinary shares$14,594K Accumulated othercomprehensive income$4,221K Derivative warrantliabilities$50,229K Accounts payable$8,090K Accrued expenses andother current...$5,092K Deferred revenue,current$3,987K Lease liability,current$23K

NewAmsterdam Pharma Co N.V. (NAMS)

NewAmsterdam Pharma Co N.V. (NAMS)